povidone-iodine and Vaginal-Diseases

Abnormal vaginal discharge (AVD) caused by a variety of reproductive tract infections is a widespread syndrome among women in India and in other developing countries. The purpose of this study was to determine whether a polyherbal formulation, Praneem, can be used for the regression of the syndrome. A phase IotaIota randomized controlled study was carried out with Praneem polyherbal tablets and Betadine vaginal pessary in 99 women with AVD. The authors found that 92% of women using Praneem were relieved of their symptoms of AVD as against 81.6% women using Betadine. Significant reduction was also seen with both treatments in lower abdominal pain, vaginal itching, and dysuria. Thus, the study indicates the efficacy of Praneem for the treatment of AVD and provides a rationale for planning a further Phase III study on a larger sample size for definitive conclusions.

Topics: Adult; Anti-Infective Agents; Chi-Square Distribution; Female; Humans; Infections; Pessaries; Phytotherapy; Plant Extracts; Plant Preparations; Povidone-Iodine; Quinine; Treatment Outcome; Vaginal Creams, Foams, and Jellies; Vaginal Discharge; Vaginal Diseases

This randomised, double-blind, multicentric clinical study compared the efficacy and tolerability of the two vaginal antiseptics, 10 mg dequalinium chloride (CAS 522-51-0, Fluomycin N) and 200 mg povidone iodine (CAS 25655-41-8), in a parallel-group design. A total of 180 patients with vaginal infections of varying etiology participated in this study (bacterial vaginosis, fluor vaginalis, vulvo-vaginal candidiasis, trichomoniasis). Patients were randomly allocated to one of the two treatment groups and were treated once per day for 6 days. Control examinations took place 5 to 7 days after the end of treatment, and 3 to 4 weeks after the first control examination. The total symptoms score, a summary score for the clinical symptoms, discharge, burning, pruritus, redness of vulva/vagina, was defined as primary efficacy parameter. The treatments at the first control examination were compared in the full analysis set using the Wilcoxon-Mann-Whitney U-test, 2-sided, thereby proving equivalence of both treatments at the 5% level. Both treatments strongly improved the symptoms of vaginal infections both on short-term and long-term follow-up. Descriptive analysis of the secondary parameters, vaginal pH, degree of purity of the vaginal flora, and number of lactobacilli in the wet mounts, supported the comparable efficacy of both therapies to restore the vaginal milieu. Analysis of the diagnostic subgroups indicated that irrespective of the diagnosis, both treatments improved the efficacy criteria as observed for the entire population. The global assessment of the therapeutic efficacy by investigators and patients supported the results of the efficacy analysis with good to very good ratings in 70-90% of the cases. A good tolerability of both preparations was observed in this study with a low number of adverse events in the test group (5.8%).

Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Infective Agents, Local; Candidiasis, Vulvovaginal; Dequalinium; Double-Blind Method; Female; Humans; Hydrogen-Ion Concentration; Middle Aged; Povidone-Iodine; Trichomonas Infections; Vaginal Discharge; Vaginal Diseases

Dequalinium chloride (CAS 522-51-0) and povidone iodine (CAS 25655-41-8) are known as antiseptic agents and used in the local treatment of vaginal infections. Clotrimazole (CAS 23593-75-1) is an anti-fungal drug and applied primarily in the therapy of vulvo-vaginal candidiasis and to a lesser extent in bacterial vaginosis and trichomoniasis. However, antimicrobial activities of those three agents in comparison to each other have not been reported so far. To address this issue the antimicrobial activities of these agents against 18 germs relevant to vaginal infections were determined. The tested species are representatives of the genera Staphylococcus, Streptococcus, Enterococcus, Listeria, Escherichia, Proteus, Gardnerella, Bacteroides, Prevotella, Porphyromonas, Candida, and Trichomonas. All micro-organisms were susceptible to dequalinium chloride with the exception of Proteus mirabilis. At a given dose, the activity of dequalinium chloride was higher as compared to the other substances. In view of its wide antimicrobial spectrum dequalinium chloride is an efficient alternative in the local therapy of vaginal infections such as fluor vaginalis, bacterial vaginosis, aerobic vaginitis, vulvo-vaginal candidiasis and trichomoniasis.

Topics: Animals; Anti-Infective Agents, Local; Antifungal Agents; Bacteria; Bacteria, Aerobic; Bacteria, Anaerobic; Candida; Clotrimazole; Culture Media; Dequalinium; Female; Fungi; Humans; Microbial Sensitivity Tests; Povidone-Iodine; Trichomonas vaginalis; Vaginal Diseases

Topics: Anti-Infective Agents; Female; Humans; Hysterectomy; Incidence; Povidone-Iodine; Vaginal Diseases

The frequency of clinical infection of the vaginal vault after hysterectomy was compared in two groups of patients, a study group treated with povidone-iodine vaginal pessaries for 36 hours pre-operatively and prepared with povidone-iodine preparations at the time of operation, and a control group given no preliminary treatment and prepared with chlorhexidine preparations at the time of operation. No significant difference was demonstrated between the two groups. Vault infection occurred in 32% of the entire series of patients (severe infection 14%) and infection correlated with the presence of pathogenic bacteria in the vagina. No significant differences in bacterial colonisation of the vagina between the two groups were demonstrated at any stage of the investigation. Preliminary preparation of the vagina with povidone-iodine pessaries is not recommended.

Topics: Adult; Aged; Bacterial Infections; Female; Humans; Hysterectomy; Middle Aged; Pessaries; Postoperative Complications; Povidone; Povidone-Iodine; Preoperative Care; Vaginal Diseases

Ten patients with vulvovaginal and cervical herpesvirus infections were treated with a regimen of external and intravaginal povidone-iodine preparations. In all but 1 case, the expected duration of symptoms and healing time were shortened. The response of cervical lesions was especially remarkable. The findings of this pilot study warrant further controlled clinical investigation.

Topics: Adult; Female; Genital Diseases, Female; Herpes Simplex; Humans; Middle Aged; Pilot Projects; Povidone; Povidone-Iodine; Uterine Cervical Diseases; Vaginal Diseases; Vulva